The Cerebral Hemodynamic and Cognitive Effects of Acute Resveratrol Administration in Young, Healthy Adults at Stimulated Altitude.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03541993
Recruitment Status : Completed
First Posted : May 31, 2018
Last Update Posted : May 31, 2018
Information provided by (Responsible Party):
Tim Eschle, Northumbria University

Brief Summary:

Background: Vaso-active polyphenols have been proposed to enhance cognitive performance. Oral administration with the non-flavonoid polyphenol, resveratrol, has been found to modulate cerebral blood flow (CBF); yet, this has not resulted in subsequent predicted benefits to cognitive performance in young, healthy samples. It has been argued that ageing populations who are noted suffer a reduction in CBF and cognition, may possess the subtle deficits to benefit from resveratrol administration. The use of hypoxia has been previously tested by this research group to mimic the decrease in cognitive functioning associated with ageing.

Objectives: The current investigation aimed to further assess if a reduced fraction of inspired oxygen (12.7% FiO2) could provide an experimental model of aging in a young, healthy sample. Moreover, the current study also aimed to assess if resveratrol can attenuate the deficits elicited by the reduction in oxygen supply via increased CBF.

Design: This repeated measures, double blind, placebo controlled, balanced design assessed the cognitive and CBF effects of resveratrol in hypoxia (equivalent to 4000 m above sea level) and normoxia (sea level).

Methods: Twenty-four participants arrived fully fasted (except water) for 12 hours before completing a baseline measure of a cognitive task battery, and taking the treatment for the day (either 500 mg resveratrol or inert placebo). Following a 45 min absorption period, participants completed 3 full repetitions of a cognitive test battery. Changes in cerebral hemodynamics were measured by near-infrared spectroscopy throughout the full testing session.

Condition or disease Intervention/treatment Phase
Hypoxia, Altitude Brain Dietary Supplement: Resveratrol Other: Placebo Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: The Cerebral Hemodynamic and Cognitive Effects of Acute Resveratrol Administration in Young, Healthy Adults at 4000 m Stimulated Altitude and at Sea Level: A Double Blind, Crossover Investigation.
Actual Study Start Date : June 7, 2016
Actual Primary Completion Date : December 22, 2016
Actual Study Completion Date : December 22, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Resveratrol

Arm Intervention/treatment
Experimental: Resveratrol Hypoxia
500 mg of trans-resveratrol, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000m above sea level.
Dietary Supplement: Resveratrol
Placebo Comparator: Placebo Hypoxia
Pharmaceutical grade fumed silica, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000 m above sea level.
Other: Placebo
Experimental: Resveratrol Normoxia
500 mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
Dietary Supplement: Resveratrol
Placebo Comparator: Placebo Normoxia
Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
Other: Placebo

Primary Outcome Measures :
  1. Cerebral blood flow [ Time Frame: 2 hours ]
    Cerebral heamodynamic response (of the prefrontal cortex) was measured at rest and during task performance. The outputs measured here were: oxygenated and deoxygenated haemoglobin concentrations. The addition of these two outputs can also detail total haemoglobin, a proxy for cerebral blood flow. All outputs were reported as concentration change in μmol / L.

  2. Cognitive performance [ Time Frame: 1 hour ]
    Participants completed a number of tasks to measure cognitive performance (as represented by the three main cognitive domains impacted by hypoxia (Memory, Speed of Attention, & Accuracy of Attention)), as part of a 15-minute cognitive battery. Cognitive tasks were scored for accuracy of responses (% correct) and the reaction time to respond to each correct response (in milliseconds (ms)). With the exception of the memory tasks which were scored for the number of correct responses and for the number error responses. Scores across the multiple cognitive tasks were combined to represent the three overall cognitive domains outlined above.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Individuals who provided informed consent.
  • Those who didn't meet any of the exclusion criteria.
  • Those who took hormonal contraception (e.g.: the pill, coil, implant, etc.) were eligible to participate in the current study.

Exclusion Criteria:

  • Individuals below 18 years or above 35 years old at the time of giving consent.
  • Individuals with Body Mass Index outside of the range 18-35 kg/m2.
  • Individuals with blood pressure greater than 140/90 HH/mg.
  • Those who smoke or have smoked.
  • Individuals who have been living (for more than 3 months) at an altitude of 2000 m or over within the past 6 months.
  • Individuals with a history of neurological, vascular or psychiatric illness (excluding depressive illness and anxiety).
  • Individuals with a current diagnosis of depression and/or anxiety.
  • Individuals with relevant learning difficulties, dyslexia, dyscalculia or colour blindness.
  • Individuals with visual impairment that cannot be corrected with glasses or contact lenses.
  • Individuals with frequent migraines that require medication (more than or equal to 1 per month).
  • Individuals with disorders of the blood.
  • Individuals with a heart disorder.
  • Individuals with a respiratory disorder that requires regular medication (Note: asthma sufferers who only take their medication occasionally/as required are eligible for this study).
  • Individuals with diabetes.
  • Individuals with any food intolerances/sensitivities.
  • Females participants who were pregnant, seeking to become pregnant, or currently lactating.
  • Individuals currently taking any prescription medications.
  • Individuals who have habitually used dietary supplements within the last month (defined as more than 3 consecutive days or 4 days in total).
  • Individuals with a history of renal or hepatic disease, or other severe diseases of the gastrointestinal tract (e.g., iron accumulation, iron utilization disorders, hypercalcaemia, hypercalciuria), that are likely to interfere with metabolism/absorption/secretion of the product under investigation.
  • Individuals with any health condition that would prevent fulfilment of the study requirements.

Responsible Party: Tim Eschle, Principal Investigator, Northumbria University Identifier: NCT03541993     History of Changes
Other Study ID Numbers: 42AX2
First Posted: May 31, 2018    Key Record Dates
Last Update Posted: May 31, 2018
Last Verified: May 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Tim Eschle, Northumbria University:
Cerebral blood flow

Additional relevant MeSH terms:
Platelet Aggregation Inhibitors
Altitude Sickness
Signs and Symptoms, Respiratory
Signs and Symptoms
Respiration Disorders
Respiratory Tract Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Enzyme Inhibitors
Antimutagenic Agents
Anticarcinogenic Agents